Evidence map›Paper›PMID 42232143›Full record

ArticleIJID regions2026

Prevalence and epidemiology of hepatitis B and hepatitis D in Uzbekistan-results from a population-based serosurvey, 2022.

Erkin Musabaev, Rania A Tohme, Elizaveta Joldasova, Shakhida Karamatova, Aybek Khodiev, Nataliya Kan, Abdulaziz Abdurasulov, Malika Khodjaeva, Botirjon Kurbanov, Zulfiya Abdurakhimova and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Erkin MusabaevResearch Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan.
Rania A TohmeDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Elizaveta JoldasovaResearch Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan.
Shakhida KaramatovaDivision of Global Health Protection, Centers for Disease Control and Prevention, Uzbekistan Country Office, Tashkent, Uzbekistan.
Aybek KhodievDivision of Global Health Protection, Centers for Disease Control and Prevention, Uzbekistan Country Office, Tashkent, Uzbekistan.
Nataliya KanResearch Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan.
Abdulaziz AbdurasulovResearch Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan.
Malika KhodjaevaResearch Institute of Virology of the Republican Specialized Scientific and Practical Medical Center of Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan.
Botirjon KurbanovCommittee for Sanitary and Epidemiological Welfare and Public Health, Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan.
Zulfiya AbdurakhimovaTashkent State Medical University, Department of Public Health and Management, Tashkent, Uzbekistan.
Dilafkor MirdjalilovDivision of Global Health Protection, Centers for Disease Control and Prevention, Uzbekistan Country Office, Tashkent, Uzbekistan.
Saleem KamiliDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Shaun ShadakerDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Nino KhetsurianiDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Uzbekistan, historically a country with high hepatitis B virus (HBV) infection endemicity, introduced infant hepatitis B vaccination in 2001 and has sustained ≥90% coverage for hepatitis B vaccine birth dose (HepB-BD) and three or more doses. In 2017, Uzbekistan initiated hepatitis B elimination activities. However, data on hepatitis B prevalence in the general population were lacking. Methods: In 2022, we conducted a serosurvey among persons aged ≥5 years using stratified cluster sampling. Blood samples were tested for markers of HBV and hepatitis D virus (HDV) infections. Results: We enrolled 9063 adults aged ≥18 years and 4092 children aged 5-17 years. Overall weighted prevalence of HBV surface antigen (HBsAg) was 4.1% (95% confidence interval, 3.1-5.0%); 13.0% (7.8-20.8%) of HBsAg-positive persons had detectable HDV ribonucleic acid (RNA). HBsAg prevalence was lowest (0.4%) among 5-14-year-olds and highest (7.3%) among 40-49-year-olds. Children who had not received HepB-BD had higher HBsAg prevalence (2.3%) than those who had received HepB-BD (0.1%, Conclusion: Successful hepatitis B vaccination resulted in low HBV infection prevalence among children, but hepatitis B remains widespread among adults in Uzbekistan. Expanding HBV prevention, screening, and treatment among adults, and maintaining high infant vaccination coverage may help achieve hepatitis B elimination in Uzbekistan.

Indexed as

EpidemiologyHepatitis BHepatitis DPrevalenceSerosurveyUzbekistan

Identifiers

PMID42232143
PMCPMC13224350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.